MANAGEMENT

Paul Wotton, Ph.D., President & CEO

Dr. Wotton joined Antares as President and Chief Operating Officer in July 2008 and was appointed President and CEO in October 2008. Previously, Dr. Wotton served as CEO of Topigen Pharmaceuticals Inc., a biotechnology company in Montreal. Prior to joining Topigen, Dr. Wotton served as Head of Global Business Development at SkyePharma PLC., and also held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton received his Ph.D. in pharmaceutical science from the University of Nottingham. He is a member of the Board of Directors of Antares Pharma and the Genaera Corporation. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTECanada.

Robert F. Apple, Executive Vice President and President of the Parenteral Products Division

Mr. Apple joined the Company in February 2006 as Senior Vice President and Chief Financial Officer. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. From 1995 to 1997, Mr. Apple was employed by Genaera Corporation, Inc., a biotechnology company, where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. as Corporate Controller. Prior to May 1994, Mr. Apple held various positions of increasing responsibility at Arthur Andersen & Company LLP. He holds a B.A. degree in accounting from Temple University and is a CPA.

Dario N. R. Carrara, Ph.D, Sr. Vice President and Managing Director

Dr. Carrara joined the Company in 1995 and relocated to our Basel, Switzerland office. He served as General Manager of Permatec’s Argentinean subsidiary from 1995 until its liquidation in 2000. Prior to joining Permatec, between 1986 and 1995, Dr. Carrara worked as Pharmaceutical Technology Manager for Laboratorios Beta, a pharmaceutical laboratory in Argentina that ranks among the top ten pharmaceutical companies in Argentina. Dr. Carrara has extensive experience in developing transdermal drug delivery devices. He earned a double degree in Pharmacy and Biochemistry, as well as a Ph.D. in Pharmaceutical Technology from the University of Buenos Aires.

Kaushik J. Dave, R.Ph., Ph. D., MBA, Senior Vice President Product Development

Dr. Dave is our Vice President of Clinical and Regulatory Affairs. Dr. Dave joined us in March 2008 from Transave Inhalation Biotherapeutics Inc., where he was Executive Director of Clinical, Regulatory Affairs, Quality Compliance and Program Management. Prior to that, Dr. Dave spent about 5 years at Palatin as Vice President Product Development where he obtained the approval of NeutroSpec, a monoclonol antibody based product, and launched the product in US. Dr. Dave was also employed by Schering-Plough from 1997 to 2001 and Merck from 1990 to 1996. Dr. Dave received his pharmacy degree from University of Bath, UK and Ph.D. in Pharmaceutical Chemistry from University of Kansas. Dr. Dave also received an M.B.A. degree from the Wharton School of the University of Pennsylvania.

Peter Sadowski, Ph.D., Senior Vice President Parenteral Products Division

Dr. Sadowski joined the Company in March 1994 as Vice President, Product Development. He was promoted to Executive Vice President and Chief Technology Officer in 1999. From October 1992 to February 1994, Dr. Sadowski served as Manager, Product Development for GalaGen, Inc., a biopharmaceutical company. From 1988 to 1992, he was Vice President, Research and Development for American Biosystems, Inc., a medical device company. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota.